Convatec Group PLC
27 August 2026
27 August 2026
Convatec Group Plc ("Convatec" or the "Company")
Non-Executive Director appointment
London, UK, 27 August 2026 - Convatec today announces the appointment of Dr Jens Viebke as a Non-Executive Director, effective immediately. He also joins the Remuneration Committee.
Jens brings more than three decades of experience developing and commercialising healthcare technologies across the life sciences and medical technology sectors, including leadership roles at Getinge, GE Healthcare Life Sciences and Amersham Biosciences. His experience spans R&D, strategy, product development, commercial operations and general management, and will complement the Board's expertise in innovation, product development and global medtech markets, supporting Convatec's continued focus on innovation-driven growth as it executes its Accelerate strategy.
Jens is currently a Non-Executive Director of Bone Support AB, Sedana Medical AB and Stille AB. He is also Chairman of Epista Life Science.
Dr John McAdam CBE, Chair, Convatec, says: "We are delighted to welcome Jens to the Board. He brings extensive international MedTech experience, having held leadership roles across research and development, product innovation, strategy and business management. His deep understanding of the innovation lifecycle, from research through to commercialisation, together with his experience of operating in highly regulated healthcare markets, will be a valuable addition to the Board as we continue to execute our Accelerate strategy and deliver sustainable growth."
Dr Jens Viebke, Non-Executive Director, Convatec, says: "I am very pleased to be joining John, Jonny and the Convatec team. The company has a strong heritage of innovation, particularly clear from its success over the past six years, a clear purpose and leading positions in attractive markets. I look forward to playing my part in supporting Convatec to advance its science and innovation agenda, as the company delivers its Accelerate strategy and creates long-term value for patients, customers, colleagues and shareholders."
Contact
Media:mediarelations@convatec.com
Analysts and investor relations:ir@convatec.com
Company Secretariat: cosec@convatec.com
Notes
Biographical information for Dr Viebke can be viewed on the company's website.
This announcement is made in accordance with Listing Rule 6.4.6. There is no further information to be disclosed under the requirements of Listing Rule 6.4.8 in relation to Dr Viebke's appointment.
Convatec Group Plc's LEI code is 213800LS272L4FIDOH92
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.